DPI developer Iconovo has announced that Galenica AB will offer cGMP manufacturing of Iconovo’s ICOone single dose disposable DPI for clinical trials, so that customers wanting to develop an inhaled drug delivered by the ICOone device have an accelerated option for producing clinical trial supplies. According to the announcement, close cooperation between the companies, both of which are located in the Malmö-Lund region of Sweden, will allow customers to schedule manufacturing on short lead times.
As part of the collaboration, Galenica is installing and qualifying a manufacturing line for the ICOone inhaler and will be responsible for approving raw material suppliers. The new manufacturing line is expected to be ready in August 2022. Previously announced development projects using the ICOone DPI include a dry powder COVID-19 vaccine from Immune System Regulation (ISR) and Monash University’s inhaled oxytocin for the prevention of postpartum hemorrhage.
Iconovo CEO Johan Wäborg commented, “The collaboration with Galenica is part of our efforts to broaden the use of ICOone among international pharmaceutical companies developing novel medicines. We will have an even more attractive and complete customer offering by being able to provide our customers with a product ready to go into early clinical trials.”
Galenical CEO Ronnie Wallin said, “I’m happy that we can offer more customers our expertise in inhalation by collaborating with Iconovo. Through this close cooperation with Iconovo, the customer can quickly and seamlessly access world-class development in inhalation, which benefits the development of novel treatments that can help patients sooner.”
Read the Iconovo press release.
